[Abdominal aortic aneurysm]

Diehm, N (2009). [Abdominal aortic aneurysm]. Internist, 50(8), pp. 972-8. Heidelberg: Springer-Verlag 10.1007/s00108-009-2362-6

[img]
Preview
Text
108_2009_Article_2362.pdf - Published Version
Available under License Publisher holds Copyright.

Download (578kB) | Preview

Abdominal aortic aneurysms (AAA) confer a substantial healthcare burden in the Western world. Surgical or endovascular therapy is indicated in patients with a maximum diameter exceeding 5.5 cm. Patients with smaller AAA must undergo a specific ultrasound surveillance program aimed at avoiding exposure to an increased risk of rupture once their AAA exceeds the threshold for active treatment. Based on improved understanding of the pathophysiology of AAA, recent years provided initial insight into potential medical treatment options. The presence of AAA is currently regarded a coronary artery disease risk equivalent. ACE inhibitors, statins and JNK-inhibitors were shown to have the potential to slow down progression. Since cigarette smoking is the main risk factor for both the development and progression of AAA, smoking cessation remains a key goal. Further prospective studies will assess the clinical efficacy of various promising drug treatment approaches aimed at slowing disease progression of small AAA and after endovascular therapy.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Diehm, Nicolas Alexander

ISSN:

0020-9554

Publisher:

Springer-Verlag

Language:

German

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:13

Last Modified:

14 Jul 2020 08:32

Publisher DOI:

10.1007/s00108-009-2362-6

PubMed ID:

19609772

Web of Science ID:

000268426300009

BORIS DOI:

10.7892/boris.32133

URI:

https://boris.unibe.ch/id/eprint/32133 (FactScience: 197059)

Actions (login required)

Edit item Edit item
Provide Feedback